Growth hormone signaling
Growth hormone and its downstream partner, insulin-like growth factor 1 (IGF-1), are involved in sleep, recovery, metabolism and lean tissue. Ipamorelin is one of several peptides discussed in relation to this pathway.
What is ipamorelin?
Ipamorelin is a five-amino-acid growth hormone secretagogue. It activates the ghrelin receptor and signals the pituitary gland to release the body's own growth hormone. It is not human growth hormone.
Ipamorelin is often described as a selective growth hormone-releasing peptide because its main hormonal effect is on growth hormone secretion. Early research found less stimulation of cortisol and adrenocorticotropic hormone (ACTH) than with older growth hormone-releasing peptides such as GHRP-2 and GHRP-6.
Once growth hormone is released, it contributes to production of IGF-1. Together, growth hormone and IGF-1 take part in processes connected to tissue maintenance, sleep, metabolism, lean tissue and exercise recovery.
Regulatory status: ipamorelin is not FDA-approved.
How ipamorelin works
The pituitary gland releases growth hormone in pulses throughout the day, with significant secretion commonly occurring during sleep. Several signaling pathways influence these pulses.
Ipamorelin activates the growth hormone secretagogue receptor, also known as the ghrelin receptor or GHS-R1a, which signals the pituitary gland to release growth hormone. Growth hormone then promotes IGF-1 production in the liver and other tissues. Growth hormone and IGF-1 are involved in:
- protein synthesis
- lean tissue maintenance
- fat metabolism
- cellular repair
- bone and connective-tissue activity
- energy use
- sleep-related restoration
Ipamorelin works through a different receptor from sermorelin and tesamorelin, which act through the growth hormone-releasing hormone (GHRH) receptor. Because the pathways are distinct, some clinicians combine ipamorelin with a GHRH peptide. Combination use has not been firmly shown to produce better long-term outcomes.
What ipamorelin is not
Ipamorelin is not an appetite-control medication and not a replacement for strength training or nutrition. Any effects connected to growth hormone and IGF-1 are not guaranteed, and training, protein intake, sleep, calorie intake, age and baseline hormone levels all influence the body's response.
Who should not use ipamorelin
Situations in which ipamorelin may not be appropriate include:
- pregnancy, planning pregnancy or breastfeeding
- active cancer or evaluation for a possible malignancy
- uncontrolled diabetes or significant glucose instability
- persistently elevated IGF-1
- serious untreated endocrine conditions or significant pituitary dysfunction
- acute critical illness
- known sensitivity to an ingredient in the formulation
- competing under athletic rules that prohibit growth hormone secretagogues
Symptoms often linked with poor recovery or sleep, such as fatigue, can have many other causes, including inadequate nutrition, thyroid dysfunction, anemia, medication effects, sleep apnea, overtraining or insufficient calorie intake.
Risks and side effects
Reported side effects include injection-site irritation, headache, flushing, dizziness, nausea, fatigue, appetite changes, fluid retention, joint discomfort and numbness or tingling in the hands. Because growth hormone signaling can affect glucose metabolism, glucose and hemoglobin A1C are commonly monitored. An excessive rise in IGF-1 is another reason for monitoring.
Because ipamorelin acts through the ghrelin receptor, appetite changes are possible and vary between people.
Ipamorelin supports growth hormone release while it is being used, and any effects may gradually diminish after it is stopped.
How ipamorelin compares with related options
Ipamorelin vs. sermorelin
Both encourage natural growth hormone release but act through different receptors. Sermorelin mimics GHRH and activates the GHRH receptor. Ipamorelin activates the ghrelin receptor.
Ipamorelin vs. tesamorelin
Tesamorelin is a more potent, longer-acting GHRH analog with clinical evidence for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy. Ipamorelin has a different mechanism and is generally discussed in relation to sleep, recovery and lean mass.
Ipamorelin vs. human growth hormone
Ipamorelin signals the pituitary gland to release growth hormone. Human growth hormone therapy delivers the hormone directly. The two have different approved uses, mechanisms, risks and monitoring requirements and are not interchangeable.
Ipamorelin vs. GLP-1 medications
GLP-1 medications act on appetite, satiety and glucose control. Ipamorelin does not have the same appetite-control effect.
Frequently asked questions
Is ipamorelin human growth hormone?
No. Ipamorelin is a growth hormone secretagogue that encourages the pituitary gland to release the body's own growth hormone. Human growth hormone supplies the hormone directly.
Does ipamorelin cause weight loss?
Ipamorelin is not an appetite-control or general weight-loss medication.
Does ipamorelin affect appetite?
It acts through the ghrelin receptor, so appetite changes are possible. Some people notice little change; others may feel hungrier.
Is ipamorelin allowed in competitive sports?
Ipamorelin is prohibited under World Anti-Doping Agency (WADA) rules. Athletes subject to testing should check with their governing organization.
This article is for general educational purposes only and is not medical advice.
